Oncology in Azerbaijan: Transition to Private Healthcare and New Market Opportunities

Introduction

The oncology care system in Azerbaijan is undergoing one of the most significant transformations in recent decades. The rising incidence of cancer, the need for advanced treatment options, and increasing pressure on public healthcare infrastructure have become key drivers of reform.

A major milestone in this transformation was reached in 2026, when legislative changes enabled private clinics to officially provide oncology services. This decision is effectively creating a hybrid healthcare model, where public and private sectors operate in parallel.

Historical Context: A Centralized Model

Until recently, oncology care in Azerbaijan was almost entirely concentrated within public institutions, primarily the National Oncology Center of Azerbaijan.

While this model ensured centralized control and basic accessibility, it had several limitations:

• limited access to innovative therapies

• high burden on infrastructure

• long waiting times

• low level of competition

With the growing number of patients, this system has become increasingly unsustainable.

Regulatory Reform in 2026: Opening the Market

In 2026, the government of Azerbaijan introduced critical amendments to the laws governing healthcare and oncology services, fundamentally reshaping the market structure.

Key elements of the reform:

• Legal authorization of private oncology care
  Private medical institutions are now officially permitted to diagnose and treat oncology patients, ending the long-standing monopoly of public providers.

• Mandatory licensing and compliance requirements
  Private clinics must obtain specialized licenses and meet strict criteria, including:

  • qualified oncology specialists

  • certified medical equipment (radiotherapy, chemotherapy units, diagnostics)

  • adherence to national clinical protocols and treatment standards

• Patient choice and referral flexibility
  Patients are no longer restricted to state institutions and can independently choose between public and private providers.

• Introduction of a mixed financing model
  Oncology care in private settings is financed through:

  • out-of-pocket payments

  • voluntary health insurance

  • potential future reimbursement mechanisms

• Gradual integration with the public system
  The reform lays the foundation for future public-private partnerships and possible inclusion of private providers in state-funded programs.

This regulatory shift marks the transition from a fully state-controlled system to a competitive and multi-channel oncology market.

Private Sector: A New Driver of Change

The inclusion of private clinics is reshaping not only access to care but also the overall development model of oncology in Azerbaijan.

1. Faster Access to Innovation

Private clinics are more agile in adopting:

• targeted therapies

• immunotherapies

• advanced diagnostic technologies

2. Shift Toward a Patient-Centric Model

The focus is increasingly on:

• service quality

• personalized treatment approaches

• faster diagnosis and treatment initiation

3. Competitive Environment

Public institutions are also beginning to adapt, improving service quality and operational efficiency.

Treatment Economics: The Key Challenge

Despite positive developments, financing remains the main constraint.

The private sector implies:

• a significant share of out-of-pocket payments

• limited insurance coverage

• high cost of innovative therapies

This creates a risk of unequal access and makes reimbursement strategies a critical factor for sustainable market development.

Implications for the Pharmaceutical Industry

The reform unlocks substantial opportunities for pharmaceutical companies.

Expanded Market Access

Private clinics are becoming:

• independent decision-making centers

• new entry points for innovative products

Faster Adoption of Therapies

Compared to public institutions, private providers:

• adopt new treatment protocols more rapidly

• are more aligned with international guidelines

Growth of High-Value Segments

Demand is expected to increase for:

• biologic oncology therapies

• orphan drugs

• personalized treatment regimens

Future Outlook: Building a New Ecosystem

In the coming years, the market is expected to evolve through:

• the emergence of specialized private oncology centers

• expansion of health insurance coverage

• development of reimbursement frameworks

• stronger presence of international pharmaceutical companies

• increasing competition among healthcare providers

In this transforming landscape, NEXA Pharm positions itself as a strategic partner for pharmaceutical and healthcare companies entering or expanding in the Azerbaijani market.

NEXA provides:

• market access strategy development

• navigation of regulatory and licensing requirements

• support in reimbursement and pricing strategy

• commercialization and promotion through private and public healthcare channels

• deep market intelligence and stakeholder mapping

With strong expertise in both public and private healthcare ecosystems, NEXA enables faster, more efficient market entry and sustainable growth.

Conclusion

The 2026 reform of oncology care in Azerbaijan represents a fundamental shift in the country’s healthcare model.

For the market, it means:

• new growth opportunities

• accelerated adoption of innovation

• increased role of private investment

For patients, it offers greater choice and the potential for improved quality of care.

For pharmaceutical companies, success will depend on the ability to navigate this evolving ecosystem.